Pediatric
Efferon NEO
The first CE‑marked single-use multimodal extracorporeal blood purification device ever purpose‑built to treat pediatric sepsis and septic shock.
Device Features
- Ready to use, sterile and pyrogen-free
- Low flow resistance, uniform flow
- Tough polycarbonate column
- Simple and reliable design eliminates connection errors
- Standard dialysis connectors for perfusion machines
- Firm and stable polymer does not crumble or dust
- No organic impurity emissions
- High hemocompatibility, low thrombogenic activity
Specifications
- Polymeric adsorbent
- Macroporous hypercrosslinked styrene-divinylbenzene copolymer with immobilized selective ligand, suspension in saline
- Inner volume
- 60 ml
- Blood filling volume
- 30 ml
- Recommended blood flow rate through the device
- 3–7 mL/min per kg of body weight of the patient
- Construction
- Symmetrical polycarbonate cylinder with two end filters, O-rings and side covers with screw caps
- Weight
- 130 g
- Diameter × length
- 51 × 134 mm
- Individual packing
- PE / PA bag
- Sterilization
- radiation sterilization
Intended use
The device is intended for extracorporeal blood purification via an extracorporeal circuit. It can be performed as isolated hemoadsorption mode or in combination with RRT, ECMO and CPB. Inflammatory mediators and endotoxin are removed from patients' circulation. Timely administration improves vital functions and hinders progression of multiple organ failure in sepsis patients.
Clinical Data
In the LASSO NEO study, hemoadsorption therapy with Efferon NEO was associated with faster resolution of multiple organ dysfunction and improved hemodynamic stabilization in pediatric sepsis patients. Treatment led to earlier discontinuation of vasopressor support and mechanical ventilation, reduced inflammatory burden, and a significantly shorter duration of intensive care support compared to standard therapy alone.
Common risks
- Hypovolemia
- Bleeding
- Catheter infection
- Air embolism
- Individual intolerance
- Hemolysis
- Increased clearance of drugs
- Decrease in platelets count
- Premature circuit clotting
Potential side effects
- Short-term hemodynamic disorders
- Risks associated with anticoagulation
- Unintended removal of other blood substances
- Hemolysis
- Thrombocytopenia, leukopenia
- Clotting in the extracorporeal circuit
- Blood loss and air embolism
- Risks related to vascular access placement
Instructions for use
Full instruction for use covering preparation, priming, perfusion and disposal protocols.
PDF will be available soon.
More products
Multimodal hemoadsorption
Clinically validated multimodal hemoadsorption technology that simultaneously removes bacterial endotoxin and excessive cytokines directly from the bloodstream, addressing key molecular drivers of sepsis and acute inflammation
